Conversely, ER- tumors developed early mutations that predisposed to genomic instability and a rapid rate of mutation and therefore transformation, which could be an added explanation for the paucity of clinically identifiable precursor lesions and interval cancers in ER—breast cancers and BRCA-1 mutation carriers. This evidence concerns the gene BRCA1 and breast carcinoma.